RELPAX Drug Patent Profile

Which patents cover Relpax, and what generic alternatives are available?

Relpax is a drug marketed by Upjohn and is included in one NDA.

The generic ingredient in RELPAX is eletriptan hydrobromide. There are twelve drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the eletriptan hydrobromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Relpax

A generic version of RELPAX was approved as eletriptan hydrobromide by ZYDUS PHARMS on June 16^th, 2017.

Summary for RELPAX

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	126
Clinical Trials:	3
Patent Applications:	3,080
Drug Prices:	Drug price information for RELPAX
What excipients (inactive ingredients) are in RELPAX?	RELPAX excipients list
DailyMed Link:	RELPAX at DailyMed

See drug prices for RELPAX

See drug sales revenues for RELPAX

Recent Clinical Trials for RELPAX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pfizer	Phase 1
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Phase 1
GlaxoSmithKline	Phase 3

See all RELPAX clinical trials

Pharmacology for RELPAX

Drug Class	Serotonin-1b and Serotonin-1d Receptor Agonist
Mechanism of Action	Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists

Paragraph IV (Patent) Challenges for RELPAX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RELPAX	Tablets	eletriptan hydrobromide	20 mg and 40 mg	021016	1	2010-03-29

US Patents and Regulatory Information for RELPAX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upjohn	RELPAX	eletriptan hydrobromide	TABLET;ORAL	021016-001	Dec 26, 2002	AB	RX	Yes	No
Upjohn	RELPAX	eletriptan hydrobromide	TABLET;ORAL	021016-002	Dec 26, 2002	AB	RX	Yes	Yes

Expired US Patents for RELPAX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upjohn	RELPAX	eletriptan hydrobromide	TABLET;ORAL	021016-001	Dec 26, 2002	5,545,644
Upjohn	RELPAX	eletriptan hydrobromide	TABLET;ORAL	021016-002	Dec 26, 2002	6,110,940
Upjohn	RELPAX	eletriptan hydrobromide	TABLET;ORAL	021016-001	Dec 26, 2002	6,110,940

International Patents for RELPAX

See the table below for patents covering RELPAX around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	222488	5HT1 antagonista hatású indolszármazékokat tartalmazó gyógyászati készítmények (PHARMACEUTICAL COMPOSITIONS CONTAINING INDOLE DERIVATIVES OF 5HT1 ANTAGONIST ACTIVITY)
Colombia	4410334	SALES DE UN DERIVADO DEL INDOL CONTRA LA MIGRANA
Bulgaria	61898

Supplementary Protection Certificates for RELPAX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0592438	SPC/GB01/023	United Kingdom		PRODUCT NAME: ELETRIPTAN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE HYDROBROMIDE SALT; REGISTERED: CH 55218 01 20001214; CH 52218 02 20001214; CH 52218 03 20001214; UK PL 00057/0452 20010212; UK PL 00057/0453 20010212; UK PL 00057/0454 20010212
0592438	C00592438/01	Switzerland		FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
0592438	02C0013	France		PRODUCT NAME: ELETRIPTAN HYDROBROMIDE; NAT. REGISTRATION NO/DATE: NL 26625 20011105; FIRST REGISTRATION: LI - IKS 55218 20001214

RELPAX Market Analysis and Financial Projection

Market Dynamics and Financial Trajectory for Relpax

Introduction

Relpax, a triptan medication developed by Pfizer, is used for the acute treatment of migraine attacks with or without aura in adults. To understand the market dynamics and financial trajectory of Relpax, it is essential to delve into various factors influencing its market position and financial performance.

Market Size and Growth of Triptan Class

The migraine therapeutics market, which includes triptans like Relpax, is projected to grow significantly. The global migraine therapeutics market is expected to reach USD 6.16 billion in 2024 and grow at a CAGR of 6.84% to reach USD 8.58 billion by 2029[1].

Competitive Landscape of Triptans

Triptans, including Relpax, are a dominant class in the migraine therapeutics market due to their higher efficacy compared to other newer agents like ditans and gepants. For instance, studies have shown that triptans are associated with higher efficacy, although they may have more adverse events compared to gepants[1].

Pricing and Compliance with Guidelines

At its introduction, Relpax was priced within the guidelines set by regulatory bodies. The prices of Relpax did not exceed the cost of therapy with comparator medicines, and they were in line with prices in other countries where the drug was sold. This compliance helped in maintaining a competitive pricing strategy[4].

Market Presence and Distribution

Relpax was introduced in several countries, including France, Germany, Italy, Sweden, the United Kingdom, the United States, and Switzerland. The drug was available in two strengths, 20mg and 40mg, and its pricing in Canada was the second highest among the comparator countries, above the median prices[4].

Financial Performance of Pfizer

Pfizer, the manufacturer of Relpax, has a robust financial profile. In 2018, Pfizer reported full-year revenues of $53.6 billion, reflecting a 2% operational growth. While Relpax is not specifically highlighted in Pfizer's annual reports as a major revenue contributor, it is part of the broader portfolio of Pfizer's pain and inflammation segment, which includes other successful drugs like Lyrica[5].

Revenue Contribution

Although specific revenue figures for Relpax are not readily available in recent reports, it is part of Pfizer's extensive portfolio of pain management drugs. Lyrica, another pain management drug by Pfizer, saw significant revenue growth, with sales of $1.8 billion in 2007, up 58% from 2006. This indicates the potential revenue contribution of pain management drugs, including triptans like Relpax, to Pfizer's overall financial performance[3].

Regulatory Approvals and Market Impact

Regulatory approvals and market launches play a crucial role in the financial trajectory of drugs like Relpax. For example, the approval of other migraine therapeutics, such as REYVOW (lasmiditan) by Eli Lilly and Company in January 2020, and VYEPTI (eptinezumab-jjmr) by Lundbeck in February 2020, highlights the competitive and dynamic nature of the migraine therapeutics market. These approvals can influence market share and revenue for existing drugs like Relpax[1].

Regional Market Dynamics

North America, particularly the United States, is a significant market for migraine therapeutics, including Relpax. The high prevalence of migraines in the U.S., with 17.1% of women and 5.6% of men reporting migraine symptoms, drives the demand for effective treatments like Relpax[1].

Strategic Activities and Market Growth

The growth of the migraine therapeutics market, including the segment for triptans like Relpax, is also driven by strategic activities such as product launches, approvals, and mergers and acquisitions. These activities by key market players help in boosting the market segment over the forecast period[1].

Challenges and Opportunities

Despite the competitive advantages of triptans, the market faces challenges such as the emergence of new pharmacologic agents like gepants and ditans. However, the higher efficacy of triptans and fewer adverse events associated with gepants compared to triptans continue to support the demand for triptans in the market[1].

Future Outlook

The future outlook for Relpax and the broader migraine therapeutics market is positive, driven by increasing awareness about migraine treatments, rising R&D spending, and the growing prevalence of migraines. The Asia Pacific region is expected to be the fastest-growing market, while North America will continue to hold a significant share[1].

Key Takeaways

• Market Growth: The global migraine therapeutics market is expected to grow at a CAGR of 6.84% from 2024 to 2029.
• Competitive Advantage: Triptans like Relpax have higher efficacy compared to newer agents.
• Pricing Strategy: Relpax was priced within regulatory guidelines, ensuring competitive pricing.
• Financial Performance: Part of Pfizer's robust financial profile, though specific revenue figures are not detailed.
• Regional Dynamics: North America, especially the U.S., is a significant market due to high migraine prevalence.
• Strategic Activities: Product launches and approvals drive market growth.

FAQs

What is the current market size of the global migraine therapeutics market?

The global migraine therapeutics market is expected to reach USD 6.16 billion in 2024[1].

Which region is expected to dominate the migraine therapeutics market?

North America is expected to dominate the overall market and maintain its dominance over the coming years[1].

What is the growth rate of the migraine therapeutics market?

The market is expected to grow at a CAGR of 6.84% from 2024 to 2029[1].

Which class of drugs is Relpax part of?

Relpax is part of the triptan class of drugs used for the acute treatment of migraines[4].

How does Relpax compare to other migraine therapeutics in terms of efficacy?

Triptans like Relpax have higher efficacy compared to newer agents like gepants and ditans, although they may have more adverse events[1].

Sources

1. Mordor Intelligence: Migraine Therapeutics Market Size & Share Analysis
2. RELX Group: RESULTS FOR THE YEAR TO 31 DECEMBER 2023
3. Pfizer: Progress & Promise
4. Patented Medicine Prices Review Board: Report on New Patented Drugs - Relpax
5. Business Wire: PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2018 RESULTS